Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc.（ADIL）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ADIL · 截至 2026年6月9日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Adial Pharmaceuticals, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ADIL 季度内部人买卖趋势
ADIL 内幕交易卖出 · ADIL 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ADIL CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ADIL 高管卖出股份 · ADIL 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 7, 2026 | Goodman Tony COO · Director | Award | 26,510 | — | Form 4 |
| Apr 7, 2026 | Schuyler Kevin Director | Award | 9,185 | — | Form 4 |
| Apr 7, 2026 | Shah Vinay CFO | Award | 17,325 | — | Form 4 |
| Apr 7, 2026 | Gilliland Robertson H. Director | Award | 9,185 | — | Form 4 |
| Apr 7, 2026 | Claiborne Cary J CEO · Director | Award | 37,985 | — | Form 4 |
| Sep 29, 2023 | Schuyler Kevin Director | Purchase | 700 | $2K | Form 4 |
| May 23, 2023 | Truluck Joseph CFO | Award | 157,500 | — | Form 4 |
| May 23, 2023 | Stilley William B. III Director | Award | 240,800 | — | Form 4 |
| May 23, 2023 | Claiborne Cary J CEO · Director | Award | 420,000 | — | Form 4 |
| Dec 30, 2022 | Stilley William B. III Director | Other | 166,667 | — | Form 4 |
| Sep 20, 2022 | Claiborne Cary J CEO · Director | Award | 75,000 | $32K | Form 4 |
| Sep 19, 2022 | Claiborne Cary J CEO · Director | Award | 25,000 | $11K | Form 4 |
| Aug 18, 2022 | Claiborne Cary J CEO | Award | 1,000,000 | — | Form 4 |
| Feb 23, 2022 | Stilley William B. III CEO · Director | Award | 250,000 | — | Form 4 |
| Dec 30, 2021 | Newman James W. Jr. Director | Purchase | 5,000 | $14K | Form 4 |
| Dec 30, 2021 | Newman James W. Jr. Director | Purchase | 10,000 | $27K | Form 4 |
| Dec 30, 2021 | Newman James W. Jr. Director | Purchase | 10,000 | $27K | Form 4 |
| Dec 23, 2021 | Schuyler Kevin Director | Gift | 312,990 | — | Form 4 |
| Nov 30, 2021 | Stilley William B. III CEO · Director | Purchase | 10,600 | $29K | Form 4 |
| Nov 29, 2021 | Stilley William B. III CEO · Director | Purchase | 10,000 | $26K | Form 4 |
| Nov 26, 2021 | Newman James W. Jr. Director | Purchase | 10,000 | $29K | Form 4 |
| Oct 4, 2021 | Johnson Bankole A. Chief Medical Officer | Sale | 200,000 | $40.00B⚡ | Form 4 |
| Apr 6, 2021 | Johnson Bankole A. Chief Medical Officer | Sale | 150,000 | $375K | Form 4 |
| Jan 26, 2021 | Stilley William B. III CEO · Director | Award | 201,109 | — | Form 4 |
| Jan 26, 2021 | Newman James W. Jr. Director | Award | 2,544 | — | Form 4 |
Johnson Bankole A.
Chief Medical Officer
日期
Oct 4
股数
200,000
均价
$200000.00
总金额
$40.00B ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ADIL 内幕交易
ADIL 内幕交易
Adial Pharmaceuticals, Inc.（ADIL）内幕交易数据来源于公司内部人（包括Goodman Tony (COO · Director), Schuyler Kevin (Director), Shah Vinay (CFO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ADIL内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Adial Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ADIL 内幕交易 · 5个问题Adial Pharmaceuticals, Inc.（ADIL）的内部人包括高管和董事，如Goodman Tony (COO · Director), Schuyler Kevin (Director), Shah Vinay (CFO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026